Skip to main content
. 2017 Apr 5;114(16):E3295–E3304. doi: 10.1073/pnas.1620052114

Fig. 1.

Fig. 1.

Attenuated clinical course of disease in nimodipine-treated mice. (A and B) Clinical course of typical (A) and atypical (B) EAE. All animals were treated on day 23 after immunization with either nimodipine (•; n = 32 in the typical EAE group, n = 18 in the atypical EAE group) or vehicle solution (☐; n = 24 in the typical EAE group, n = 22 in the atypical EAE group). (C) Sensomotor deficits in nimodipine-treated (n = 10) and vehicle-treated (n = 11) mice were rated using a balance score. *P ≤ 0.05; ***P ≤ 0.001 by Mann–Whitney test.